Effects of atomoxetine on growth in children with attention-deficit/ hyperactivity disorder following up to five years of treatment

Thomas J. Spencer, Christopher J. Kratochvil, R. Bart Sangal, Keith E. Saylor, Charles E. Bailey, David Dunn, Daniel A. Geller, Charles D. Casat, Robert S. Lipetz, Rakesh Jain, Jeffrey H. Newcorn, Dustin D. Ruff, Peter D. Feldman, Amanda J. Furr, Albert J. Allen

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objective: To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year study of the efficacy and safety of treatment with atomoxetine. Methods: North American patients, 6-17 years old at study entry (N = 1,312) and with Diagnostic and Statistical Manual of Mental Disorders,4th edition (DSM-IV) ADHD, were studied under open-label atomoxetine treatment. Sixty-one were studied up to 5 years. Results: After 1 month's treatment, patients weighed less than expected from their starting percentiles relative to population norms, with a maximum shortfall at 15 months and a return to expected weight by 36 months. Patients were slightly shorter than expected after 12 months, reaching a maximum shortfall at 18 months and returning to expected height by 24 months. Patients in the top quartile for body mass index (BMI) or weight at baseline, and those in the third quartile for height, showed 5-year decreases from expected values. Those below median height at baseline showed increases relative to expected values. Conclusions: These interim results indicate that continuous atomoxetine treatment for up to 5 years has little or no long-term effect on juvenile growth and final stature for most patients, although persistent decreases from expected may occur in some patients who are larger than average before treatment.

Original languageEnglish
Pages (from-to)689-699
Number of pages11
JournalJournal of Child and Adolescent Psychopharmacology
Volume17
Issue number5
DOIs
StatePublished - Nov 1 2007

Fingerprint

Attention Deficit Disorder with Hyperactivity
Growth
Diagnostic and Statistical Manual of Mental Disorders
Therapeutics
Weights and Measures
Atomoxetine Hydrochloride
Body Mass Index
Pharmacology
Safety
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effects of atomoxetine on growth in children with attention-deficit/ hyperactivity disorder following up to five years of treatment. / Spencer, Thomas J.; Kratochvil, Christopher J.; Sangal, R. Bart; Saylor, Keith E.; Bailey, Charles E.; Dunn, David; Geller, Daniel A.; Casat, Charles D.; Lipetz, Robert S.; Jain, Rakesh; Newcorn, Jeffrey H.; Ruff, Dustin D.; Feldman, Peter D.; Furr, Amanda J.; Allen, Albert J.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 17, No. 5, 01.11.2007, p. 689-699.

Research output: Contribution to journalArticle

Spencer, TJ, Kratochvil, CJ, Sangal, RB, Saylor, KE, Bailey, CE, Dunn, D, Geller, DA, Casat, CD, Lipetz, RS, Jain, R, Newcorn, JH, Ruff, DD, Feldman, PD, Furr, AJ & Allen, AJ 2007, 'Effects of atomoxetine on growth in children with attention-deficit/ hyperactivity disorder following up to five years of treatment', Journal of Child and Adolescent Psychopharmacology, vol. 17, no. 5, pp. 689-699. https://doi.org/10.1089/cap.2006.0100
Spencer, Thomas J. ; Kratochvil, Christopher J. ; Sangal, R. Bart ; Saylor, Keith E. ; Bailey, Charles E. ; Dunn, David ; Geller, Daniel A. ; Casat, Charles D. ; Lipetz, Robert S. ; Jain, Rakesh ; Newcorn, Jeffrey H. ; Ruff, Dustin D. ; Feldman, Peter D. ; Furr, Amanda J. ; Allen, Albert J. / Effects of atomoxetine on growth in children with attention-deficit/ hyperactivity disorder following up to five years of treatment. In: Journal of Child and Adolescent Psychopharmacology. 2007 ; Vol. 17, No. 5. pp. 689-699.
@article{bfc9827589874555869db12da5191f90,
title = "Effects of atomoxetine on growth in children with attention-deficit/ hyperactivity disorder following up to five years of treatment",
abstract = "Objective: To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year study of the efficacy and safety of treatment with atomoxetine. Methods: North American patients, 6-17 years old at study entry (N = 1,312) and with Diagnostic and Statistical Manual of Mental Disorders,4th edition (DSM-IV) ADHD, were studied under open-label atomoxetine treatment. Sixty-one were studied up to 5 years. Results: After 1 month's treatment, patients weighed less than expected from their starting percentiles relative to population norms, with a maximum shortfall at 15 months and a return to expected weight by 36 months. Patients were slightly shorter than expected after 12 months, reaching a maximum shortfall at 18 months and returning to expected height by 24 months. Patients in the top quartile for body mass index (BMI) or weight at baseline, and those in the third quartile for height, showed 5-year decreases from expected values. Those below median height at baseline showed increases relative to expected values. Conclusions: These interim results indicate that continuous atomoxetine treatment for up to 5 years has little or no long-term effect on juvenile growth and final stature for most patients, although persistent decreases from expected may occur in some patients who are larger than average before treatment.",
author = "Spencer, {Thomas J.} and Kratochvil, {Christopher J.} and Sangal, {R. Bart} and Saylor, {Keith E.} and Bailey, {Charles E.} and David Dunn and Geller, {Daniel A.} and Casat, {Charles D.} and Lipetz, {Robert S.} and Rakesh Jain and Newcorn, {Jeffrey H.} and Ruff, {Dustin D.} and Feldman, {Peter D.} and Furr, {Amanda J.} and Allen, {Albert J.}",
year = "2007",
month = "11",
day = "1",
doi = "10.1089/cap.2006.0100",
language = "English",
volume = "17",
pages = "689--699",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Effects of atomoxetine on growth in children with attention-deficit/ hyperactivity disorder following up to five years of treatment

AU - Spencer, Thomas J.

AU - Kratochvil, Christopher J.

AU - Sangal, R. Bart

AU - Saylor, Keith E.

AU - Bailey, Charles E.

AU - Dunn, David

AU - Geller, Daniel A.

AU - Casat, Charles D.

AU - Lipetz, Robert S.

AU - Jain, Rakesh

AU - Newcorn, Jeffrey H.

AU - Ruff, Dustin D.

AU - Feldman, Peter D.

AU - Furr, Amanda J.

AU - Allen, Albert J.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Objective: To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year study of the efficacy and safety of treatment with atomoxetine. Methods: North American patients, 6-17 years old at study entry (N = 1,312) and with Diagnostic and Statistical Manual of Mental Disorders,4th edition (DSM-IV) ADHD, were studied under open-label atomoxetine treatment. Sixty-one were studied up to 5 years. Results: After 1 month's treatment, patients weighed less than expected from their starting percentiles relative to population norms, with a maximum shortfall at 15 months and a return to expected weight by 36 months. Patients were slightly shorter than expected after 12 months, reaching a maximum shortfall at 18 months and returning to expected height by 24 months. Patients in the top quartile for body mass index (BMI) or weight at baseline, and those in the third quartile for height, showed 5-year decreases from expected values. Those below median height at baseline showed increases relative to expected values. Conclusions: These interim results indicate that continuous atomoxetine treatment for up to 5 years has little or no long-term effect on juvenile growth and final stature for most patients, although persistent decreases from expected may occur in some patients who are larger than average before treatment.

AB - Objective: To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year study of the efficacy and safety of treatment with atomoxetine. Methods: North American patients, 6-17 years old at study entry (N = 1,312) and with Diagnostic and Statistical Manual of Mental Disorders,4th edition (DSM-IV) ADHD, were studied under open-label atomoxetine treatment. Sixty-one were studied up to 5 years. Results: After 1 month's treatment, patients weighed less than expected from their starting percentiles relative to population norms, with a maximum shortfall at 15 months and a return to expected weight by 36 months. Patients were slightly shorter than expected after 12 months, reaching a maximum shortfall at 18 months and returning to expected height by 24 months. Patients in the top quartile for body mass index (BMI) or weight at baseline, and those in the third quartile for height, showed 5-year decreases from expected values. Those below median height at baseline showed increases relative to expected values. Conclusions: These interim results indicate that continuous atomoxetine treatment for up to 5 years has little or no long-term effect on juvenile growth and final stature for most patients, although persistent decreases from expected may occur in some patients who are larger than average before treatment.

UR - http://www.scopus.com/inward/record.url?scp=35848960802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848960802&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.0100

DO - 10.1089/cap.2006.0100

M3 - Article

VL - 17

SP - 689

EP - 699

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 5

ER -